secwatch.observer — SEC 8-K summary
======================================

Issuer:     ENDRA Life Sciences Inc. (NDRA)
CIK:        0001681682
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001654954-24-005981
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ENDRA Life Sciences reports expected Q1 2024 net loss of ~$2.8M, zero revenue; files for public offering
--------------------------------------------------------------------------------

- Expected Q1 2024 net loss of approx. $2.8M vs. $2.9M in Q1 2023; zero revenue in both quarters.
- As of March 31, 2024, total assets ~$5.0M, cash ~$1.1M, working capital only ~$54k.
- Filed Form S-1/A for public offering of common stock and warrants; terms not disclosed.
- Preliminary results are unaudited and subject to final closing and audit adjustments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424005981/0001654954-24-005981-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1681682/000165495424005981/ndra_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-24-005981

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer